This firm-fixed-price delivery order was awarded to Societal CDMO San Diego, LLC (a division of Recro Pharma, Inc.) by the National Cancer Institute, part of the National Institutes of Health at the Department of Health and Human Services. The $546,667.00 contract is for the production of an engineering batch, current Good Manufacturing Practice (cGMP) batch, delivery, and shelf-life study of ammonium tetrathiomolybdate (ATTM) capsules to support a clinical trial for a potential cancer...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $780,240 delivery order contract to Regimed Medical of Frederick, Maryland. Under the terms of the contract, Regimed Medical will provide 112 blisters of 150mg Nilotinib capsules and 16 blisters of 200mg Nilotinib capsules in support of the DHHS, NIH, NCI, DCTD, CTEP. The fixed price contract runs from September 20, 2023 through September 19, 2024 and will be performed in Frederick,...
This is a delivery order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Societal Cdmo San Diego, LLC, a small disadvantaged business contract development and manufacturing organization (CDMO). The $505,500.00 contract is for the development and manufacture of a novobiocin capsule product, including a 36-month shelf-life study, in support of NIH's cancer research programs. The award is issued under the Drug Formulation...
This federal contract award is for "CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) DEVELOPMENT OF NCGC00413972 FOR PRECLINICAL SAFETY EVALUATION AND CLINICAL TRIAL" and was issued to Curia Global Inc., doing business as Amri. The contract, valued at $907,791.77, is a delivery order under the "CRO Support for NCATS Drug Substance Development and Manufacture" indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The National Center for Advancing Translational...
This is a delivery order awarded to Regimed Medical, a minority-owned small disadvantaged business located in O'Fallon, Missouri, under a $6.34 million Indefinite Delivery Contract (IDC) with the National Institutes of Health (NIH) National Cancer Institute. The delivery order, valued at $219,850.00, is for the procurement of 200 mg nilotinib tablets to support the NIH's Division of Cancer Treatment and Diagnosis and Cancer Therapy Evaluation Program. This requirement is not set-aside and is...
This is a federal contract award to Societal CDMO San Diego, LLC (doing business as Irisys Inc.), a small disadvantaged business, to produce 1,000 vials of the drug Triapine (NSC-663249) for the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract is a Delivery Order with a cost plus fixed fee pricing type, has a ceiling value of $137,972.00, and an ultimate completion date of May 9, 2020....
This is a delivery order contract awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Societal CDMO San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business. The $704,621.50 firm-fixed-price contract is for the dosage form development, manufacture, and stability studies of the investigational drug AVE-1625 (drinabant). The work is being performed in San Diego, California. This delivery order is...
This is a delivery order awarded by the National Institute on Drug Abuse (part of the National Institutes of Health under the Department of Health and Human Services) to Bachem Americas, Inc., a foreign-owned for-profit manufacturer of pharmaceutical ingredients. The $1,050,039.90 firm fixed-price contract is for the manufacture of 200 grams of current Good Manufacturing Practice (cGMP) parathyroid hormone-related protein (PTH-rP). The work is being conducted under the parent "CRO Support...
This is a $36,506,288.06 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to Theradex Systems, Inc. for clinical trials monitoring services. The contract has a performance period from May 1, 2017 to April 30, 2022. The contract supports NCI's Experimental Therapeutics Clinical Trials Network (ETCTN), National Clinical Trials Network (NCTN), and National Community Oncology Research Program (NCORP), as well as the NCI COVID-19 in Cancer Patients Study (NCCAPS) and the...
This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...